IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION

Track this case

Case overview

Case Number:

9:20-md-02924

Court:

Florida Southern

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Multi-district Litigation, Class Action

Judge:

Robin L. Rosenberg

Firms

Companies

Sectors & Industries:

July 01, 2024
GSK Wants Lab's Zantac Whistleblower Suit Moved To Florida

GlaxoSmithKline wants a Connecticut laboratory's federal whistleblower lawsuit moved from Pennsylvania to Florida, where a West Palm Beach court has already overseen four years of a multidistrict litigation that GSK said was touched off by the same lab's claims that Zantac breaks down into a cancer-causing chemical.
February 07, 2023
Zantac Plaintiffs Must File Separate Complaints, Judge Says

A Florida federal judge ruled Tuesday that tens of thousands of consumers claiming they developed cancer after taking the heartburn medication Zantac could not be combined in multi-plaintiff personal injury cases in the wake of the court's decision that there was insufficient evidence the drug's active ingredient caused cancer.
January 27, 2023
Generic Zantac Makers Want Final Judgment In Fla. MDL

A group of companies that manufacture generic forms of the heartburn medication Zantac on Friday asked a Florida federal court to issue a final judgment throwing out claims against them in a sprawling multidistrict litigation.
January 26, 2023
Zantac Suits Consolidated In NY After Fla. MDL Tossed

New York's Litigation Coordinating Panel on Thursday consolidated more than 40 suits alleging that the heartburn medication Zantac, or ranitidine, contains cancer-causing chemicals just over a month after a Florida federal judge threw out most claims in a sprawling nationwide multidistrict litigation against pharmaceutical companies that make or distribute the drug.
December 06, 2022
Fla. Court Axes Zantac MDL Claims, Citing Lack Of Experts

A Florida federal judge on Tuesday handed a major win to drugmakers battling multidistrict litigation over the heartburn medication Zantac, dismissing all claims against Pfizer, GlaxoSmithKline, Boehringer Ingelheim and Sanofi and finding that "no scientist outside this litigation" has concluded that the drug's active ingredient causes cancer.
October 05, 2022
Patients Urge Fla. Court To Review New Zantac Cancer Study

Several patients suing GlaxoSmithKline in multidistrict litigation over its Zantac heartburn medication have filed an expedited motion urging a judge to consider a new study that may show a connection between four types of cancer and the drug's main ingredient.
August 17, 2022
Zantac Plaintiff Dismisses Suit 1 Week Before Trial

A 79-year-old Illinois man whose trial was set to be the first to begin in sprawling state and federal litigation over whether a chemical in Zantac heartburn medication causes cancer has notified a state court that he intends to voluntarily dismiss his suit, one week before that trial was scheduled to start.
May 19, 2022
Valisure Can't Get Fees For Quashed Subpoena In Zantac MDL

A Florida magistrate judge on Thursday denied medical testing laboratory Valisure LLC's bid for attorney fees associated with responding to a quashed subpoena in multidistrict litigation over allegations that the heartburn drug Zantac contains a carcinogen, saying defendants in the case had justification for seeking the documents.
March 04, 2022
Valisure Wants Fees For Quashed Subpoena In Zantac MDL

Valisure LLC asked for an award of the legal expenses the pharmacy incurred producing documents and fighting a subpoena in multidistrict litigation over heartburn drug Zantac, arguing that forcing it to bear the costs could allow drugmakers to chill investigations into their products by forcing whistleblowers to incur litigation expenses.
January 28, 2022
Drugmakers Won't Get Discovery From Valisure In Zantac MDL

A Florida magistrate judge on Friday quashed GlaxoSmithKline's subpoenas for more information from pharmacy Valisure LLC in multidistrict litigation over heartburn drug Zantac after finding the information sought in the subpoenas has limited importance to the litigation.

← Previous
1
2
3
Next →